MODERN APPROACHES TO THE TREATMENT OF GOUT AND STUDY OF THE RANGE OF MEDICINES FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE MUSCULOSKELETAL SYSTEM ON THE MODERN PHARMACEUTICAL MARKET OF UKRAINE
DOI:
https://doi.org/10.11603/2312-0967.2023.3.14165Keywords:
gout, medicines, herbal products, extractsAbstract
The aim of the work. To analyze the data of the scientific literature on modern approaches to the treatment of gout, to investigate the range of medicines used for the prevention and treatment of inflammatory diseases of the musculoskeletal system, to establish the role of herbal preparations in the treatment of these diseases and to determine promising active pharmaceutical ingredients for the development of new medicines in this direction actions.
Materials and Methods. Data from the State Register of Medicinal Products of Ukraine and the ATC classification system of the electronic resource Compendium.online were used to study the assortment of medicines used for the prevention and treatment of inflammatory diseases of the musculoskeletal system. Methods of information search and literature data analysis were used.
Results and Discussion. Current approaches to the treatment of gout include: lifestyle modification to control risk factors for cardiovascular complications, accompanied by hyperuricemia; treatment of an acute attack of gouty arthritis with the use of nonsteroidal anti-inflammatory drugs, colchicine, glucocorticoids, as well as therapy aimed at reducing the level of uric acid and prevention of new attacks of acute gout. However, the prevention of systemic lesions of internal organs deserves more and more attention, to which insufficient attention is paid.
A study of the assortment of medicines used for the treatment of gout, registered in the State Register of Medicines of Ukraine, was carried out. It was established that 31 medicines inhibiting the formation of uric acid were registered for the treatment of gout, including 9 medicines based on allopurinol and 22 medicines based on febuxostat, and 2 medicines that do not affect the metabolism of uric acid, based on colchicine. All medicines of this group are produced in the form of tablets. An analysis of the assortment of all medicines that affect the musculoskeletal system showed the presence of only a small number of herbal preparations in this group of medicines, most of which are semi-solid preparations for topical use containing essential oils. Medicinal products of plant origin that affect the musculoskeletal system are also represented by liquid medicines for topical application and only three preparations for oral use in the form of tablets and capsules, which contain an Harpagophytum procumbens extract, avocado and soybean oil, and Colchicum autumnale extract. Dietary supplements with an anti-inflammatory effect on the joints in the form of herbal teas are also available on the pharmaceutical market of Ukraine.
Conclusions. Taking into account modern approaches to the treatment of gout, medicinal products based on plant raw materials, which have anti-inflammatory and analgesic effects, contribute to the reduction of pain and swelling, reduce the level of uric acid and have a hepatoprotective effect, deserve great attention. Promising for the creation of new medicines for the prevention and treatment of gout are plant extracts obtained from medicinal plant raw materials, in particular Silybi mariani fructs, Gentianae roots, Sаmbuci flowers, Betulae and Cynara scolymus leaves.
References
Polstyanoi AO. [Gout: a brief historical review]. Ukrainian Journal of Medicine, Biology and Sport. 2019;4(2): 33-7. Ukrainian.
Holbrook HS, Calandruccio JH. Management of Gout in the Hand and Wrist. Orthop Clin North Am. 2023,54;3: 299-308. DOI: 10.1016/j.ocl.2023.02.003.
Dalbeth N, Frampton C, Fung M. Predictors of Patient and Physician Assessments of Gout Control. Arthritis Care Res (Hoboken). 2023;75;6: 1287-91. DOI: 10.1002/acr.25046.
Yakymenko OO, Hrytsenko MV. [Effectiveness of bioflavonoids in the treatment of patients with gout against the background of metabolic syndrome]. Art of Medicine. 2019;3: 73-7. Ukrainian.
Holovach IYu, Yegudina ED. [Gout: an old acquaintance within the framework of modern recommendations]. Practicing physician. 2019;8(2): 9-27. Ukrainian.
Yakymenko OO., Hrytsenko MV, Kravchuk OE. [The effect of low doses of colchicine on the clinical course and kidney function in patients with gout against the background of metabolic syndrome]. Odesa Medical Journal. 2019; 1: 56-60. Ukrainian.
Kuts TV, Moroz GZ, Tkachuk IM. [The clinical course of gout in military personnel at the current stage]. Ukrainian journal of military medicine. 2021;2(2): 43-8. Ukrainian.
Khimion LV, Yashchenko OB, Sytyuk TO. [Modern strategy of management of patients with gout]. Family medicine. 2019;1: 6-12. Ukrainian.
[Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction]. Q. He, TN. Mok, TH. Sin, et al. JMIR Public Health Survey. 2023;7(9): e45943. DOI: 10.2196/45943.PMID: 37285198
Orel MA, Andreychyn SM. [Damage to various organs and systems in hyperuricemia and gout (literature review)]. Advances in Clinical and Experimental Medicine. 2022;2: 12-20. Ukrainian.
Kwok TS, Kuriya B, Hawker G. Serum Urate Monitoring amongst Older Adults with Gout Initiating Urate Lowering Therapy in Ontario, Canada. Arthritis Care Res (Hoboken). 2023;29. DOI: 10.1002/acr.25167. Online ahead of print.PMID: 37248652
Pupin TI, Moroz KA, Vinogradova OM. [Generalized periodontitis and gout: comparison of pathogenetic mechanisms of development (literature review)]. Clinical Dentistry. 2021;1: 44-53. Ukrainian.
Vakalyuk IP, Seredyuk NM, Vaceba MO. [Effectiveness of metabolic therapy in comorbid condition – arterial hypertension, obesity and gout]. Art of medicine. 2019;1: 27-31. Ukrainian.
Kondratyuk VE, Tarasenko OM, Natrus LV, Ponomaryova IG. [Hypouricemic effectiveness of synbiotics in complex treatment of patients with gout]. Ukrainian therapeutic journal. 2019;1: 75-84. Ukrainian.
[State Register of Medicinal Products of Ukraine]. http://www.drlz.kiev.ua/
updated EULAR evidence-based recommendations for the management of gout. P. Richette, M. Doherty, E. Pascual. Ann. Rheum. Dis. 2017;76(1): 29-42. DOI: 10.1136/annrheumdis-2016-209707.
Vaceba MO. [Effectiveness of the metabolic effect of meldonium dihydrate in comorbid conditions - arterial hypertension, obesity and gout]. Advances in clinical and experimental medicine. 2019;1: 34-9. Ukrainian.
Andreychyn SM, Mudra UO. [Assessment of enterosorption in patients with gout]. Bukovynskyi Medical Bulletin. 2020;24(1): 10-17. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
